
|Articles|February 12, 2017
DIR Fee Controversy Highlights AJPB Week in Review
Author(s)Davy James, Managing Editor
Top articles of the week from The American Journal of Pharmacy Benefits.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means
2
Brain Inflammation May Not Drive Persistent Long COVID Symptoms, New Imaging Study Finds
3
Beyond Weight Loss: Exploring the Renal and Anti-Inflammatory Benefits of High-Dose Semaglutide
4
ADA 2026: The 2026 ADA Standards – A Pharmacist's Guide to Cardiorenal Risk Reduction
5






































































































































